改善了基于AAV9的基因治疗设计,用于SURF1相关的利氏综合征,毒性最小
Qinglan Ling1,2, Matthew Rioux3, Harrison Higgs3
1Department of Genetic & Cellular Medicine, Horae Gene Therapy Center, UMass Chan Medical School, Worcester, MA 01605, USA.
Molecular therapy. Methods & clinical development
|September 2, 2025
概括
这项研究开发了一种改善的SURF1相关的李氏综合征基因疗法,降低了细胞毒性,同时保持了疗效. 新的载体为这种神经退行性疾病提供了更安全的治疗候选.
科学领域:
- 线粒体生物学
- 神经遗传学
- 基因治疗
背景情况:
- 与SURF1相关的利氏综合征是一种严重的早期神经退行性疾病,影响线粒体功能.
- 目前的治疗方法缺乏疾病修饰能力.
- 之前的基因疗法显示有效,但由于蛋白质过度表达导致野生型大鼠的细胞毒性.
研究的目的:
- 开发一种改善的基因治疗载体来治疗与SURF1相关的利氏综合征.
- 为了减轻与原始载体设计观察到的细胞毒性.
- 提高基因替代疗法的安全性.
主要方法:
- 使用修改后的促进剂和多基因化序列, 设计了一种针对SURF1相关的新基因治疗载体.
- 在小鼠和老鼠模型中评估了载体的有效性和安全性.
- 评估了SURF1蛋白表达水平和细胞毒性.
主要成果:
- 新的载体设计实现了与原始载体相似的治疗效果.
- 减少SURF1蛋白表达导致小鼠和大鼠的细胞毒性最小.
- 与最初的设计相比,改进的载体表现出了有利的安全性.
结论:
- 转基因治疗载体代表了与SURF1相关的利氏综合征的有希望的治疗候选者.
- 降低蛋白质表达是减少载体诱导的细胞毒性的关键.
- 需要进一步的转化研究来推进这种治疗.
更多相关视频
相关概念视频
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...
00:59Gene Therapy
Gene therapy is a technique where a gene is inserted into a person’s cells to prevent or treat a serious disease. The added gene may be a healthy version of the gene that is mutated in the patient, or it could be a different gene that inactivates or compensates for the patient’s disease-causing gene. For example, in patients with severe combined immunodeficiency (SCID) due to a mutation in the gene for the enzyme adenosine deaminase, a functioning version of the gene can be inserted. The...